Last C$0.18 CAD
Change Today -0.005 / -2.70%
Volume 5.0K
As of 11:13 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

medifocus inc (MFS) Snapshot

Open
C$0.18
Previous Close
C$0.19
Day High
C$0.18
Day Low
C$0.18
52 Week High
10/7/13 - C$0.25
52 Week Low
06/17/13 - C$0.12
Market Cap
21.1M
Average Volume 10 Days
84.6K
EPS TTM
C$-0.05
Shares Outstanding
117.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIFOCUS INC (MFS)

Related News

No related news articles were found.

medifocus inc (MFS) Related Businessweek News

No Related Businessweek News Found

medifocus inc (MFS) Details

Medifocus Inc. develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform that precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It develops APA 1000 breast cancer treatment system that is in Phase III clinical trials; and Prolieve thermodilatation system for the treatment of benign prostatic hyperplasia. The company is based in Toronto, Canada.

25 Employees
Last Reported Date: 03/3/14

medifocus inc (MFS) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: C$240.0K
Chief Financial Officer
Total Annual Compensation: C$75.0K
Chief Operating Officer
Total Annual Compensation: C$200.0K
Compensation as of Fiscal Year 2013.

medifocus inc (MFS) Key Developments

Medifocus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Medifocus Inc. reported earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported revenue was CAD 1.35 million compared to revenue of CAD 630,150 in the comparable period of fiscal 2013, representing an increase of 114%. The company reported a net loss of CAD 1.54 million or CAD 0.013 per share, for the third fiscal quarter of 2014 compared to a net loss of CAD 2.1 million or CAD 0.021 per share, in the prior year period. For the nine months, the company reported revenue was CAD 3,892,178, compared to revenue of CAD 943,431 in the prior year period, representing an increase of CAD 2,948,747, or 313%, over the comparable period of fiscal 2013.

Medifocus Inc. Provides Updates on APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III Clinical Study

Medifocus Inc. announced that VM Medical Center in Montreal, its Principal Investigational Site in Canada for its APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III clinical study, has successfully treated its first patient enrolled. Dr. John R. Keyserlingk, MD is the Principal Investigator at the VM Medical Center in Montreal, Canada. The VM Medical Center is the large non-public private breast center in Canada. The Pivotal Phase III Breast Cancer treatment study has been approved to be initiated by both the USA Food and Drug Administration and the Canadian Bureau of Medical Devices (BMD). The USA Principal Investigational site has already been initiated at the University of Oklahoma Breast Institute under the supervision of the Company's US Principal Investigator, Dr. William C. Dooley, MD. The goal of the 238 patient Medifocus-sponsored randomized Phase III study is to demonstrate that preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large breast cancer tumors in the intact breast. Combining heat with chemotherapy before surgery can potentially shrink the tumor so that it can be removed in a breast conserving surgery (lumpectomy), thus reducing the need of a mastectomy.

Medifocus Inc. Announces Earnings Results for the Second Quarter and Six Month Ended September 30, 2013

Medifocus Inc. announced earnings results for the second quarter and six month ended September 30, 2013. For the second quarter, the company's revenue for the second quarter of fiscal 2014 ended September 30, 2013 was CAD 1.23 million compared to revenue of CAD 313,281 in the second quarter of fiscal 2013, representing a 294% increase. The net loss for the second quarter of fiscal 2014 was CAD 1.47 million or CAD 0.013 per share compared with net loss of CAD 1.02 million or CAD 0.014 per share a year ago. The net loss for the period is primarily due to the significant resources the Company has expended in rolling out the Prolieve(R) system and the increase in general and administrative expenses following the acquisition and commercialization of the Prolieve(R) systems by the company. For the six months, the company's revenue for the six months ended September 30, 2013 reached a record CAD 2.55 million, representing a 40% increase over total revenue in fiscal year 2013 of CAD 1.81 million. The revenue increase for both periods reflects the continued successful rollout and strong market acceptance of the company's Prolieve(R) Thermodilatation System for treatment of Benign Prostatic Hyperplasia (BPH). The net loss for the first six months was CAD 2.70 million or CAD 0.023 per share compared with net loss of CAD 1.43 million or CAD 0.019 per share. The net loss for the period is primarily due to the significant resources the Company has expended in rolling out the Prolieve(R) system and the increase in general and administrative expenses following the acquisition and commercialization of the Prolieve(R) systems by the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MFS:CN C$0.18 CAD -0.005

MFS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.46 USD +0.105
Celsion Corp $3.13 USD +0.10
Medtronic Inc $58.18 USD +0.13
Urologix Inc $0.15 USD +0.0009
View Industry Companies
 

Industry Analysis

MFS

Industry Average

Valuation MFS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 23.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIFOCUS INC, please visit www.medifocusinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.